Publish time: 2023-10-11 00:00:00
12A-1101001
PCT and TW pending
Abnormal glycosylation acts as a protective shield, rendering pathogens and tumor antigens immune-resistant. We've identified STT3A as a critical player in the glycosylation of SARS-CoV-2 spike and SLAMF7. In response, we've developed two innovative solutions: 4G10-ADC and anti-SLAMF7 ADC. These cutting-edge antibody-drug (NGI-1) conjugates target STT3A, reducing virus infectivity and bolstering antibody-mediated neutralization. Additionally, they counteract the excessive glycosylation of SLAMF7 on tumor cells, rendering them more susceptible to macrophage engulfment. Our approach, centered on ADC-induced deglycosylation, offers a unique strategy to combat the impact of glycosylation in both cancer and pathogen infections.
- Precise and specific treatment
- Small molecular inhibitor is released by lysozyme
- Low off-target toxicity
- Antibody efficacy and immunoenhancement
- Cancer therapy
- Immunotherapy
- Monoclonal antibody therapy
Li, Chia-Wei
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

ANTIBODY-DRUG CONJUGATE FOR REDUCING GLYCOSYLATION OF MEMBRANE GLYCOPROTEIN